Additional lesions identified by genomic microarrays are associated with an inferior outcome in low‐risk chronic lymphocytic leukaemia patients

Author:

Rigolin Gian Matteo1ORCID,Traversa Alice2,Caputo Viviana2,Del Giudice Ilaria3,Bardi Antonella1,Saccenti Elena1,Raponi Sara3ORCID,Ilari Caterina3,Cafforio Luciana34,Giovannetti Agnese5,Pizzuti Antonio2,Guarini Anna6,Foà Robin3,Cuneo Antonio1

Affiliation:

1. Hematology Section St. Anna University Hospital Ferrara Italy

2. Department of Experimental Medicine Sapienza University Rome Italy

3. Hematology, Department of Translational and Precision Medicine Sapienza University Rome Italy

4. GenomeUp S.r.l. Rome Italy

5. Clinical Genomics Unit Fondazione IRCCS Casa Sollievo della Sofferenza S. Giovanni Rotondo Italy

6. Department of Molecular Medicine Sapienza University Rome Italy

Abstract

SummaryWe explored the relevance of genomic microarrays (GM) in the refinement of prognosis in newly diagnosed low‐risk chronic lymphocytic leukaemia (CLL) patients as defined by isolated del(13q) or no lesions by a standard 4 probe fluorescence in situ hybridization (FISH) analysis. Compared to FISH, additional lesions were detected by GM in 27 of the 119 patients (22.7%). The concordance rate between FISH and GM was 87.4%. Discordant results between cytogenetic banding analysis (CBA) and GM were observed in 45/119 cases (37.8%) and were mainly due to the intrinsic characteristics of each technique. The presence of additional lesions by GM was associated with age > 65 years (p = 0.047), advanced Binet stage (p = 0.001), CLL‐IPI score (p < 0.001), a complex karyotype (p = 0.004) and a worse time‐to‐first treatment in multivariate analysis (p = 0.009). Additional lesions by GM were also significantly associated with a worse time‐to‐first treatment in the subset of patients with wild‐type TP53 and mutated IGHV (p = 0.025). In CLL patients with low‐risk features, the presence of additional lesions identified by GM helps to identify a subset of patients with a worse outcome that could be proposed for a risk‐adapted follow‐up and for early treatment including targeted agents within clinical trials.

Funder

Division of Antarctic Infrastructure and Logistics

Ministero dell’Istruzione, dell’Università e della Ricerca

Università degli Studi di Ferrara

Publisher

Wiley

Subject

Hematology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3